Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 2/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.37 |
| ▸ | BRD4 | O60885 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 3/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.33 |
| ▸ | NNMT | P40261 | 2/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8360444 | 0.80 | TSHR (0.54) | TSHRMKNK1CDC7CREBBPBRD4 | |
| SCHEMBL11746648 | 0.74 | TSHR (0.40) | TSHRCREBBPBRD4LMNAGAA | |
| SCHEMBL3308170 | 0.74 | TSHR (0.60) | TSHRMKNK1CDC7BRD4LMNA | |
| SCHEMBL21333673 | 0.74 | TSHR (0.60) | TSHRMKNK1CDC7LMNAACHE | |
| SCHEMBL30285537 | 0.74 | TSHR (0.60) | TSHRMKNK1CDC7LMNAACHE | |
| SCHEMBL14991244 | 0.74 | TSHR (0.60) | TSHRMKNK1CDC7PIM1 | |
| SCHEMBL14991559 | 0.74 | TSHR (0.60) | TSHRMKNK1CDC7PIM1 | |
| SCHEMBL21470711 | 0.74 | TSHR (0.60) | TSHRMKNK1CDC7CREBBPBRD4 | |
| SCHEMBL2170999 | 0.74 | TSHR (0.60) | TSHRMKNK1CDC7BRD4LMNA | |
| SCHEMBL14991246 | 0.74 | TSHR (0.60) | TSHRMKNK1CDC7PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160271108-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | AGENEBIO, INC. | 2016-09-22 | — | — | US | disclosed |
| US-20110212928-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110053981-A1 | Methods and Compositions Using Cholinesterase Inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20100168174-A1 | Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-05-27 | — | — | US | disclosed |
| US-7563808-B2 | Methods for treating cognitive impairments or dementia | EISAI CO., LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| US-20090131480-A1 | Dihydropyridine Compounds for Neurodegenerative Diseases and Dementia | EISAI CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090042939-A1 | Methods and Compositions Using Cholinesterase Inhibitors | EISAI CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090042940-A1 | METHODS AND COMPOSITIONS USING CHOLINESTERASE INHIBITORS | EISAI CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20080312189-A1 | Cadasil Treatment with Cholinesterase Inhibitors | EISAI CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080167343-A1 | Methods and compositions using cholinesterase inhibitors | EISAI CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080045500-A1 | Nerve Regeneration Stimulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-02-21 | — | — | US | disclosed |
| US-20070129402-A1 | Donepezil; pharmacokinetics; single-dose administration of the formulation to a patient provides a blood plasma level profile with a dosage-corrected Cmax | EISAI RESEARCH INSTITUTE (US) | 2007-06-07 | — | — | US | disclosed |
| US-20070021397-A1 | Neurocyte protective agent | EISAI CO., LTD. (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20060172992-A1 | Therapeutic agent for overactive bladder resulting from cerebral infarction | EISAI CO., LTD. (JP) | 2006-08-03 | — | — | US | disclosed |
| US-20060135507-A1 | Therapeutic agent for overactive bladder involved in aging | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | GRIN1, GRIN2A, GRIN3A | TSHR 4157/4885HTT 937/4885MKNK1 2413/4885 |
| US-20080167343-A1 | Methods and compositions using cholinesterase inhibitors | PSEN1, BACE1, PSENEN | TSHR 253/4885HTT 406/4885MKNK1 226/4885 |
| US-20100168174-A1 | Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain | ACHE, CHRNA5, CHRNA2 | TSHR 1994/4885HTT 4182/4885MKNK1 2426/4885 |
| US-20070021397-A1 | Neurocyte protective agent | CHAT, GAP43, NES | TSHR 4607/4885HTT 277/4885MKNK1 3505/4885 |
| US-20090131480-A1 | Dihydropyridine Compounds for Neurodegenerative Diseases and Dementia | CHRNA5, GRIN1, GRIK5 | TSHR 2819/4885HTT 20/4885MKNK1 3142/4885 |
| US-20080045500-A1 | Nerve Regeneration Stimulator | ACHE, NGF, GAP43 | TSHR 1772/4885HTT 4109/4885MKNK1 3260/4885 |
| US-20160271108-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, BACE1, GRIN2A | TSHR 1591/4885HTT 352/4885MKNK1 2282/4885 |
| US-20060135507-A1 | Therapeutic agent for overactive bladder involved in aging | ACHE, BPHL, GLA | TSHR 3517/4885HTT 2142/4885MKNK1 4335/4885 |
| US-20070129402-A1 | Donepezil; pharmacokinetics; single-dose administration of the formulation to a patient provides a blood plasma level profile with a dosage-corrected Cmax | CYP3A5, SLC6A2, SLC6A4 | TSHR 2784/4885HTT 506/4885MKNK1 4247/4885 |
| US-20090042939-A1 | Methods and Compositions Using Cholinesterase Inhibitors | PSEN1, BACE1, PSENEN | TSHR 253/4885HTT 406/4885MKNK1 226/4885 |
| US-20060172992-A1 | Therapeutic agent for overactive bladder resulting from cerebral infarction | ACHE, CHAT, BCHE | TSHR 3098/4885HTT 3218/4885MKNK1 2876/4885 |
| US-20080312189-A1 | Cadasil Treatment with Cholinesterase Inhibitors | NOTCH3, NOTCH2, NOTCH4 | TSHR 4830/4885HTT 1399/4885MKNK1 3613/4885 |
| US-20110053981-A1 | Methods and Compositions Using Cholinesterase Inhibitors | PSEN1, BACE1, PSENEN | TSHR 253/4885HTT 406/4885MKNK1 226/4885 |
| US-20110212928-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | TSHR 4373/4885HTT 954/4885MKNK1 2271/4885 |
| US-20090042940-A1 | METHODS AND COMPOSITIONS USING CHOLINESTERASE INHIBITORS | PSEN1, BACE1, PSENEN | TSHR 253/4885HTT 406/4885MKNK1 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.